Professional Documents
Culture Documents
November 3, 2017
Introduction
Most common female cancer
Accounts for 32% of all female cancer
211,300 new cases yearly and rising
40,000 deaths yearly
Gross Anatomy
epithelium
Lobular tissue
Presentation
Breast lump
Abnormal mammogram
Axillary lympadenopathy
Metastatic disease
Familial Breast Cancer
Cause 5-10% of all cancer and 25% in women
<30 y/o
BRCA2
Causes 40% of familial breast CA
50-70% - breast
15-45% - ovarian
Increased risk for prostate, colon
BRCA1
50-70% - breast
20-30% - ovarian
Increased risk for prostate, pancreatic, laryngeal,
Screening Mammography
Recommendations
Biannually or annually in 40-49 y/o
Annually in >50 y/o
15% relative risk reduction
Birads
0 - Incomplete assessment; need additional imaging evaluation
1 - Negative; routine mammogram in 1 year recommended
2 - Benign finding; routine mammogram in 1 year recommended
3 - Probably benign finding; short-term follow-up suggested (3%)
4 - Suspicious abnormality; biopsy should be considered (30%)
5 - Highly suggestive of malignancy; appropriate action should be
taken (94%)
Biopsy techniques
FNA
Diagnostic and therapeutic in cystic lesions
Core needle
U/S guided or sterotatic
90% effective in establishing diagnosis
Atypia need excision
Sterotatic
Needle localization
Excision biopsy
Risk of Future Invasive Breast Carcinoma
Based on Histologic Diagnosis from Breast
Biopsies
No Increase
Adenosis
Apocrine metaplasia
Cysts, small or large
Mild hyperplasia (>2 but <5 cells deep)
Duct ectasia
Fibroadenoma
Fibrosis
Mastitis, inflammatory
Periductal mastitis
Squamous metaplasia
3. Papillary type
4. Comedo type*
Lobular carcinoma
Invasive
Histology
A. Ductal NOS
B. Lobular
C. Mucinous
D. Tubular
E. Medullary
Staging
Tumor
Tis: in situ
T1: <2cm
T2: 2-5cm
T3: >5cm
T4: invasion of skin or chest wall
Node
N1: 1-3 axillary nodes or int mam node
N2: 4-9 axillary nodes or palpalbe int mam node
N3: >10 nodes or combo of axillary and int mam nodes
{mic micoroscopic posivitiy, mol molecular posiivity
Metastasis
Staging
Modified Radical Mastectomy
Entire breast tissue and Level I & II nodes
Survival at 10 yrs
Negative nodes 82% (5% local recurrence)
Positive nodes 48% (5% local recurrence)
Benefits
Decreases risk of ca in other breast by 47-80%
Draw backs
Increases endometrial ca risk by 2.5, PE 3.0, DVT 1.7
Source: NSABP P-1 trial
Chemotherapy
Early Breast Cancer Trialists Collaborative
Group
Decreases recurrence (12%) and death (11%) regardless of
nodal status
Indications
All patients except node negative, <10mm tumors
Regimens
Multidrug combination chemotherapy
Tamoxifen or aromatse inhibitor - ER positive tumors
Herceptin (trastuzumab) HER2/neu positive tumors
NSABP B-31 33% reduction in risk of death
Other breast cancers
Inflammatory ca
Carcinoma invading lymphatic ducts
Chemotherapy, mastectomy, radiation
Mastectomy
Other breast cancers
Phyllodes tumor
<1% of breast tumors
Age 30-45
Similar in appearance to fibroadenoma
4% recurrence after excision
0.9% axillary spread
Radiation, chemotherapy, tamoxifen ??